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Abstract  
Myelination is a sequential process that is tightly controlled by a number of intrinsic and extrinsic 
factors. Any CNS disease in which the neuronal myelin sheath is damaged is referred to as 
demyelinating disease. The present work was designed to study the histopathological, 
ultrastructural and immunohistochemical changes in rat brain, mainly corpus callosum (CC), 
following oral administration of cuprizone (CPZ), and the role of N-acetylcysteine (NAC) in 
reducing these changes. Demyelination was induced by CPZ administration for short (4Ws) and 
long (8Ws) periods.  NAC was given concomitantly and sequentially for similar periods. 
Spontaneous recovery after cessation of CPZ followed by no medication was also investigated. At 
the end of each experimental period, both cerebral hemispheres were extracted and prepared for 
light and electron microscopic examination and immuno-histochemical study.  The obtained results 
showed a direct proportion between the duration of CPZ administration and the severity of 
demyelination. The co-administration of CPZ and NAC, had a fair protective impact that was 
stronger than the sequential administration of the two drugs. Incomplete spontaneous remyelination 
was observed after cessation of CPZ, being more evident in short than in long period group, 
indicating that when CPZ administration is prolonged, remyelination is delayed.  
In the light of the above results, it could be concluded that NAC has neuroprotective effects and has 
the potential to be a novel therapeutic approach for the treatment of demyelinating diseases such as 
multiple sclerosis; however, treatment should begin as soon as the disease manifests.  
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INTRODUCTION 
Myelination is an operation that is highly orchestrated by many intrinsic and extrinsic 
variables, step-by-step [1].Many animal studies have shown that the neuronal activity along axons 
modulates its degree of myelination [2]. Although the mechanism of myelin formation is not yet 
fully understood; it is modelled as a staged process, from differentiation of oligodendrocyte 
progenitor cells (OPCs) to oligodendrocytes (OLs), followed by ensheathment of axons and 
ultimately maturation of the sheath [3].  
Demyelinating disease is defined as any CNS disease in which the neuronal myelin sheath 
is damaged [4]. Based on their pathogenesis, demyelinating CNS diseases can be categorized into: 
inflammatory diseases {e.g.: multiple sclerosis (MS) and acute-disseminated encephalomyelitis}, 
viral infection, hypoxic-ischemic types and demyelination caused by acquired metabolic disorders 
or focal compression of the brain [5]. Oligodendrocytes are vulnerable to oxidative stress-mediated 
damage, cytotoxicity, deprivation of the trophic factor and activation of apoptotic pathways [6]. 
Demyelination and inflammation are pathological features of MS and both are assumed to 
contribute to axon damage and consequently to cerebral atrophy that is prevalent in later stages of 
the disease [7]. MS demyelinating lesions are multifocal and spread in the brain affecting both 
white and grey matter. After demyelinating events, remyelination frequently occurs, but it is often 
incomplete. Consequently, understanding remyelination failure and designing strategies to restore 
myelin sheath is one of the challenges of MS science [8].  
In MS pathogenesis, oxidative stress is a key factor that alleviates the migration of 
leukocytes, thereby leading to OLs damage and axonal injury. In the CNS of MS patients, reactive 
oxygen and nitrogen species are formed mainly by activated macrophages and microglia, the 
resident macrophage of the brain, and are responsible for demyelination and axon disruption. 
Various inflammatory and oxidative stress mediators such as cytokines and chemokines are 
secreted by activated microglia [9, 10].  
Cuprizone (CPZ) is a copper-chelator of low molecular weight that affects the metabolism 
of cells and contributes to reversible demyelination in both gray and white matter [11].  Feeding 
with cuprizone results in the death of mature oligodendrocytes, whereas other CNS cell types are 
not affected because oligodendroglia is more vulnerable to copper deficiency [12]. The toxic effect 
of CPZ on mature OLs results in the inhibition of the mitochondrial activity of the copper-
dependent cytochrome oxidase and monoamine oxidase enzymes, resulting in mitochondrial 
dysfunction either through enlargement or clustering, this is followed by their apoptosis [13]. 
Oligodendrocytes death is thought to result from persistent mitochondrial stress brought on by both 
the toxic effect of the drug and the inherent immune response [14]. Microglia and reactive 
astrocytes populate in the demyelination areas and secrete pro-inflammatory cytokines (e.g: TNF-α, 
interleukin-1β and interferon-γ) that govern the demyelination process [15].  
N acetylcysteine (NAC) is an effective free radicals scavenger of reactive oxygen species 
(ROS) but its key function as a therapeutic antioxidant stems from its role as a cysteine and 
glutathione synthesis precursor [16, 17]. Previous studies provide evidence for the therapeutic 
potential of NAC in multiple psychiatric and neurological disorders and claimed that to its anti-
oxidant, anti-inflammatory and anti-apoptosis effects [18-23].  
Recently, Zhou et al.2020 [24] indicated that NAC boosts remyelination process via 
promoting oligodendrocyte survival in oxidative stress-related conditions through the  increase in 
GSH levels  and upregulation of heme oxygenase-1 (HO-1), a cytoprotective enzyme, that play a 
fundamental  role in oligodendrocytes protection.  
The aim of the this work is to investigate the possible therapeutic role of N-acetylcysteine in 
cuprizone - induced demyelination in the brain, particularly corpus callosum, of male albino rat and 
to elucidate the possible spontaneous recovery (remyelination) after cessation of cuprizone. 
 
MATERIALS AND METHODS 
Material 
Chemicals. Cuprizone (CPZ) (bis-cyclohexanone-oxaldihydrazone) was supplied by Sigma-
Aldrich Company in the form of powder, which was dissolved in distilled water and given orally by 
gastric gavage tube to the rats in a dose of 2 gm/kg of body weight (b.w.) [25]  
 N-Acetylcysteine (NAC) was supplied by Sedico Company as effervescent instant granules 600 mg 
/ml, which were dissolved in distilled water and given orally by gastric gavage tube in a dose of 50 
mg/kg b.w. [26]. The gastric gavage tube was left in position for 20 seconds to prevent regurgitation 
and ensure administration of the calculated doses. 
Animals. Seventy adult male albino rats of Sprague Dawley strain, four-months of age and 
weighing 150-250g were used in the current study. They were obtained from the animal house, 
Faculty of Medicine, Cairo University and housed in metal cages, five rats/cage under standard 
laboratory and environmental conditions. The rats were used according to ethics of animal care and 
use committee (ACUC) of Cairo University. 
Experimental design. Rats were divided into four groups: 
— Group I (Control group): comprised 30 rats and subdivided into two subgroups: 
— Subgroup I-A (Normal control group): comprised 15 rats, they received no medications. Five rats 
were sacrificed after four, eight and sixteen weeks respectively; 
— Subgroup I-B (Sham control group): comprised 15 rats, they were given distilled water orally; 
daily for four, eight and sixteen weeks respectively; 
— Group II (CPZ treated group, short duration): comprised 15 rats and divided into three subgroups 
as follows: 
— Subgroup II-A: Each rat received the calculated dose of CPZ orally; daily for four successive 
weeks; 
— Subgroup II-B: Each rat received the calculated doses of CPZ concomitant with NAC orally; daily 
for four successive weeks; 
— Subgroup II-C: Each rat received the calculated dose of CPZ daily orally for four successive 
weeks followed by the calculated dose of NAC orally; daily for another four successive weeks. 
— Group III (CPZ treated group, long duration): comprised 15 rats and subdivided into three 
subgroups; 5 rats each as follows: 
— Subgroup III A: Each rat received the calculated dose of CPZ for eight weeks; 
— Subgroup III-B: Each rat received the calculated doses of CPZ concomitant with NAC orally; daily 
for eight successive weeks; 
— Subgroup IIIC: Each rat received the calculated doses of CPZ  followed by NAC orally; daily for 
eight successive weeks; 
— Group IV (CPZ recovery group): comprised 10 rats and subdivided into two subgroups; 5 rats 
each: 
— Subgroup IV-A: Each rat received the calculated dose of CPZ daily orally for four successive 
weeks; then no medication received for another four successive weeks; 
— Subgroup IV-B: Each rat received the calculated dose of CPZ daily orally for eight successive 
weeks; then no medication received for another eight successive weeks.  
 
Methods 
At the end of the experimental period, the rats were sacrificed after anaesthetization with 
50ml/kg subcutaneous injection of thiopental sodium and the brains were extracted and rinsed under 
distilled water to remove any surface blood, followed by immersion in ice-cold normal saline for 5 
min then placed on cold metal plate, finally two cerebral hemispheres were sectioned along the 
sagittal suture and prepared for the following studies: 
Light microscopic examination. The extracted brains were immersed in formalin 10 %, for two 
days. Then washed under running tap water, and then embedded in paraffin. Sagittal sections of 7 
microns thickness were made and stained with:     
— Luxol fast blue stain (LFB): to visualize the myelin in nerve sheath. Myelin stained blue while the 
nuclei and Nissl substance stained violet or red [27]; 
— Hematoxylin and Eosin stain (Hx&E): for standard histological examination [28]. 
Immuno-histochemical study [29]. Myelin basic protein antibody (MBP-antibody) (Thermo 
Fischer, Labvision,USA): is an unconjugated rabbit polyclonal antibody . A positive myelin fibers 
reaction is visible as a brown precipitate under the microscope, and the nuclei appear light blue.  
Electron microscopic examination (TEM). Freshly prepared sections from brain samples of 




Myelinated nerve fibers of CC. Light microscopic examination of myelination in control 
groups revealed densely packed, myelinated and parallel arranged fibers. The oligodendrocytes 
nuclei appeared well defined, rounded, darkly stained and arranged in longitudinal rows parallel to 
the nerve fibers that they myelinate (Figs. 1 a, b).The nerve fibers and oligodendrocytes nuclei 
showed strong positive myelin basic protein reaction (Fig. 1c).Electron microscopic examination 
showed variable sized densely packed axons. Axons were seen surrounded by thick electron dense 
myelin sheath and electron lucent intact cytoplasm (Fig. 1d).The oligodendrocyte appeared ovoid 
with dark nucleus surrounded by regular nuclear envelope and contains clumped chromatin material 
beneath the nuclear envelope and throughout the nucleoplasm. It is seen surrounded by electron 
lucent cytoplasm (Fig. 1e). 
Concomitant administration of NAC protects from CPZ-induced demyelination more 
efficiently than the Consecutive treatment by the two drugs. Light microscopic examination of 
demyelination in CPZ-treated group for 4 weeks showed multiple areas of unpacked partially 
demyelinated nerve fibers with axonal disruption and splitting, partial loss of oligodendrocytes 
nuclei, most of them appeared dispersed and showed faint staining and karyorrhexis, others 
appeared circumscribed and darkly stained, Few nuclei are seen oriented parallel to the nerve fibers 
(Figs. 2a, b).The nerve fibers and oligodendrocytes nuclei  showed moderate positive myelin basic 
protein reaction (Fig. 2c). CC nerve fibers of CPZ and NAC treated group displayed that most of 
the nerve fibers exhibited fair myelination and appeared well arranged and packed. Few specimens 
showed focal axonal disruption and fragmentation. The oligodendrocytes nuclei appeared preserved 
but disorganized. Some of them are seen oriented in linear rows parallel to the nerve fibers. The 
nuclei appeared rounded with darkly stained. Few nuclei appeared flattened and small in size with 
faint staining and karyorrhexis (Figs. 2d, e).The nerve fibers showed strong positive myelin basic 
protein reaction associated with positive oligodendrocytes nuclei reaction (Fig. 2f). CPZ followed 
by NAC-treated group revealed demyelinated and unpacked nerve fibers with localized areas of 
axonal disruption and splitting. The oligodendrocytes nuclei were preserved but dispersed. Some of 
them were seen oriented parallel to the nerve fibers. Most of the nuclei appeared rounded faintly 
stained (Figs. 2g, h). The nerve fibers showed moderate positive myelin basic protein reaction and 
positive oligodendrocytes nuclei reaction (Fig. 2i). Weak spontaneous remyelination is detected 
in the short duration (CPZ4Ws) recovery group after 4 weeks of CPZ cessation. The CC nerve 
fibers of this recovery group appeared fragmented, demyelinated and disorganized with large 
cytoplasmic vacuoles being more evident near the periventricular region. Oligodendrocytes nuclei 
appeared of small size, rounded, darkly stained and dispersed, while others appeared flattened (Figs. 
2j, k). The nerve fibers displayed weak positive myelin basic protein reaction and moderate positive 
oligodendrocytes nuclei reaction (Fig. 2l). 
Electron microscopic examination of the CPZ-treated group for 4 weeks revealed that the 
nerve fibers were unpacked with narrow gapping in between, multiple thin myelinated and scanty 
unmyelinated axons were seen. Few thick myelinated axons were also seen. Most of the myelin 
sheaths appeared redundant or irregular and displayed focal areas of lamellar splitting. Some axons 
showed axonal cytoplasmic degeneration, others showed inclusion bodies in their cytoplasm (Fig. 
3a). The oligodendrocytes in this group appeared ovoid containing dark nucleus with regular nuclear 
envelope and clumped chromatin both beneath the nuclear envelope and throughout the 
nucleoplasm. They were seen surrounded by multiple variable sized thin and thick myelinated axons 
with degenerated cytoplasm (Fig. 3b). The CC nerve fibers of CPZ and NAC-treated group were 
predominantly thin myelinated with few well myelinated ones. Some of their myelin sheaths 
appeared redundant with splitting and showed variable degrees of axonal cytoplasmic degeneration 
and inclusion bodies (Fig. 3c). The oligodendrocytes nuclei were ovoid and dark with regular 
nuclear envelope and surrounded by rarified cytoplasm. They were seen in close relation to the 
surrounding axons (Fig. 3d). The CPZ followed by the NAC-treated group displayed unpacked 
nerve fibers with narrow gaps in between. A lot of thin myelinated and unmyelinated axons were 
seen. The myelin sheaths appeared redundant with focal lamellar splitting. Variable degrees of 
cytoplasmic degeneration were seen (Fig. 3e). The oligodendrocytes nuclei appeared ovoid and dark 
with regular nuclear envelope and clumped chromatin. The surrounding cytoplasm showed 
connection to multiple variable sized thin myelinated axons (Fig. 3f). The CPZ-recovery group 
(4Ws after CPZ cessation) displayed unpacked axons with wide areas of gapping in between. The 
demyelination patches showed predominantly thin myelinated axons, few unmyelinated axons with 
ratified axonal cytoplasm. Myelin sheaths appeared irregular, split and abnormally folded. Rarified 
axonal cytoplasm with absence of inclusion bodies were observed (Fig. 3g). The oligodendrocytes 
nuclei appeared ovoid and dark with regular nuclear envelope and clumped chromatin. The 
surrounding cytoplasm appeared electron lucent with multiple vacuoles and few abnormal folded 
myelin sheaths with no evidence of axonal connection (Fig. 3h). 
CPZ supplementation for long duration (8Ws) produces massive demyelination and 
lessens the protective effects of NAC. Light microscopic examination of demyelination in CPZ-
treated group for 8 weeks revealed marked demyelination, fragmentation and complete 
disorganization of CC nerve fibers. All oligodendrocytes nuclei appeared disorganized and of small 
size, irregular shaped with faint staining and variable degrees of karyorrhexis and karyolysis (Figs. 4 
a, b). The nerve fibers showed negative myelin basic protein reaction with poor oligodendrocytes 
nuclei reaction (Fig. 4c). CPZ and NAC-treated group showed that the CC nerve fibers appeared 
partially demyelinated and unpacked, with scanty areas of splitting in the myelin sheath and 
vacuolated cytoplasm. The oligodendrocytes nuclei appeared preserved and arranged in linear rows 
between the unpacked nerve fibers. They appeared rounded, darkly stained apart from scanty nuclei 
which showed faint staining and others appeared flattened (Figs.4 d, e). The nerve fibers showed 
weak positive myelin basic protein reaction with moderate positive oligodendrocytes nuclei reaction 
(Fig. 4f). CPZ followed by NAC-treated group showed  that the CC nerve fibers appear diffusely 
demyelinated, unpacked and disorganized with wide areas of axonal fragmentation, splitting and 
cytoplasmic vacuolation. Few nerve fibers appeared well arranged. Partial loss of oligodendrocytes 
nuclei, with the remaining ones appearing dispersed. Some of them appeared rounded and 
circumscribed, Others appeared of small size with poor staining and karyolysis (Figs. 4 g, h).The 
nerve fibers displayed weak positive myelin basic protein reaction and positive oligodendrocytes 
nuclei reaction (Fig. 4i).  
Poor spontaneous remyelination is detected in the long duration (CPZ 8Ws) recovery 
group after 8 weeks of CPZ cessation. The nerve fibers of the long duration recovery group 
appeared markedly disorganized and demyelinated with diffuse poor staining and marked 
cytoplasmic vacuolation. Few oligodendrocytes nuclei were seen parallel to the nerve fibers, most of 
them were dispersed and small sized with partial loss of their population. The nuclei exhibited dark 
and faint staining (Figs. 4j, k).The nerve fibers and oligodendrocytes nuclei showed weak positive 
myelin basic protein reaction (Fig. 3-9c). 
Electron microscopic examination of the CPZ-treated group for 8 weeks revealed massive 
axonal degeneration. The remaining axons were thin myelinated with split myelin sheath and wide 
gaps in between, these gaps contain remnants of fragmented degenerated axons and fragmented 
collapsed myelin sheaths (Fig. 5a). The oligodendrocytes displayed oval heterochromatic nuclei 
with localized nuclear envelope indentation. Most oligodendrocytes exhibited completely 
degenerated rarified cytoplasm (Figs. 5b). CPZ and NAC-treated group showed disorganized 
nerve fibers with narrow gaps in between. Multiple thin myelinated and unmyelinated axons were 
detected. Few specimens demonstrated multiple compact folded myelin sheath fragments and 
inclusion bodies (Fig. 5c). The oligodendrocytes nuclei appeared ovoid and dark with regular 
nuclear envelope and clumped chromatin. The surrounding cytoplasm showed large vacuoles and 
inclusion bodies with close connection to the demyelinated axons (Fig. 5d). CPZ followed by 
NAC-treated group showed a lot of unpacked thin myelinated and demyelinated axons. Scanty 
myelinated small sized axons with irregular deformed myelin sheaths were seen. Axons displayed 
cytoplasmic rarefaction with scanty inclusion bodies (Fig. 5e). The oligodendrocytes nuclei 
appeared ovoid and dark with irregular nuclear envelope and diffuse chromatin clumps. The 
surrounding cytoplasm appeared electron dense with abundant mitochondria and secretory granules. 
It was seen connected to multiple thin myelinated axons (Fig. 5f). The CPZ-recovery group (after 
8Ws of CPZ cessation) showed unpacked axons with wide gaps in between. The demyelination 
patches showed predominantly multiple fragmented unmyelinated axons and scanty thin myelinated 
axons. Some myelin sheaths appeared irregular and split. Almost all axons showed cytoplasmic 
rarefaction (Fig. 5g). Oligodendrocytes nuclei appeared rounded, dark and surrounded by electron 
dense vacuolated cytoplasm that contains multiple abnormal folded myelin sheaths with evidence of 
connection to few axons (Fig. 5h).  
DISCUSSION 
The development of animal models of human diseases is critical. Over the past 60 years, 
studies of multiple sclerosis (MS) and other demyelinating CNS disorders have closely followed 
this approach [31]. 
In the current study, cuprizone (CPZ) intoxication model is used to induce CNS 
demyelination. That was in accordance with MacArthur and Papanikolaou (2014) [32], who stated 
that marked nerve demyelination in animals is induced by oral administration of CPZ, likewise, 
Vega-Riquer et al. (2019) [33] indicated that CPZ targets many enzymes such as ceruloplasmin, 
which impairs the activity of the copper dependent cytochrome oxidase, decreases oxidative 
phosphorylation and causes degenerative oligodendrocyte changes. Eventually, this cascade of 
events results in demyelination. Male albino rats were used in the present research to study the 
various aspects of demyelination in the CC, which was similar to other study by Franco et al. 
(2008) [34]. Hibbits et al. (2009) [35] and Steelman et al. (2012) [36] have documented that female 
rats are more resistant to CPZ-induced toxic demyelination, which could be due to potential 
hormonal and genetic influences. 
In line with the current study, Skripuletz et al. (2011) [37] focused on the demyelinating 
effects of CPZ in the CC, as it is an oligodendrocyte-rich structure and the degree of demyelination 
may easily be achieved. 
Systemic intoxication by CPZ was produced by daily administration of the drug for four and 
eight week’s durations to induce CC nerve demyelination, this was in agreement with Oakden et al. 
(2017) [25]. On the other hand, Taraboletti et al. (2017) [38] used CPZ fed mice model for two and 
six weeks and demyelination was observed at the third week and maximum demyelination reached 
at the fifth or six weeks. Administration of CPZ in subgroup III-A produced severe pathological 
changes more than in subgroup II-A indicating the presence of direct proportion between the 
duration of administration and the severity of nerve demyelination , this was compatible with 
Zendedel et al. (2013) [12] who reported that partial demyelination of CC nerve fibers occurred 
after two weeks of CPZ intoxication, and called this process as (acute demyelination); while 
complete demyelination occurred after five to six weeks. On the other hand, Acs and Komoly 
(2012) [39] documented the incidence of severe demyelination after three weeks of CPZ 
administration associated with massive macrophage infiltration and astrocytosis in the 
demyelinated areas. 
In the current model of CPZ intoxication, The examined groups illustrated variable degrees 
of axonal degeneration, loss of oligodendrocytes and gapping between nerve fibers; these  were in 
accordance to Freeman et al. (2015) [40]; Van Munster et al. (2015) [41]; Grothe et al. (2016) [42] 
and  Vargas and Tyor (2017) [43]. These changes were more pronounced in subgroup III-A. Ultra-
structurally, Subgroup III-A revealed thin myelinated axons with axonal degeneration, 
fragmentation, axonal loss, fragmented collapsed myelin sheaths and oligodendrocytes nuclear 
changes.  Subgroup II-A, on the other hand, displayed mainly thick myelinated nerve fibers with 
redundant myelin sheaths and broken focal areas of splitting. Zendedel et al. (2013) [12] declared 
that demyelinated axons are more susceptible to damage due to the absence of trophic support from 
myelin sheaths, which are vital for maintaining axonal integrity. Craner et al. (2004) [44] reported a 
hypothesis of demyelination-related axonal damage, which could be due to the demyelinated axons' 
increased energy requirements to perform action potential, which could make demyelinated axons 
more prone to destructive processes. 
In addition, gapping between the demyelinated nerve fibers in subgroup III-A were more 
than subgroups II-A, which was in accordance to a study made by Mierzwa et al. (2015) [45] who 
explained that the abnormal gaps between nerve fibers could slow information-processing speed, 
which is a common deficit in MS patients. Similar observations were clarified by Tobin et al. 
(2011) [46] and Hibbits et al. (2012) [47], who stated that CPZ induces extreme microglial 
phagocytosis of damaged myelin, and most cases of axons damage do not regenerate again. 
Glutathione is an antioxidant that naturally exists in neurons that protects against oxidative 
harm. In the brain and the periphery of MS patients, glutathione levels have been found to be 
depleted [48]. Monti et al. (2020) [49] stated that, due to restricted antioxidants such as glutathione, 
the brain of MS patients is susceptible to high oxidative stress. Cacciatore et al. (2012) [50] and Wu 
and Batist (2013) [51] demonstrated that direct administration of glutathione is difficult due to its 
poor absorption and stability, which limits its bioavailability. Therefore, in a trial to raise 
endogenous glutathione levels, N-acetyl cysteine (NAC) is used in current research. This was 
consistent with Skvarc et al. (2017) [52] who reported that NAC is a glutathione precursor with 
potent antioxidant, pro-neurogenesis and anti-inflammatory properties. likewise, Zhou et al. (2020) 
[24] clarified that NAC promoted  murine oligodendrocyte survival  in oxidative stress-related 
conditions  through the elevation of glutathione levels and upregulation of heme oxygenase-1 (HO-
1), a cytoprotective enzyme, play a principle role in oligodendrocyte protection and consequently 
boosted remyelination. 
In the present study, the combined administration of NAC with CPZ in subgroups II-B and 
III-B reduced CC demyelination changes as compared to subgroups II-C and III-C. NAC led to 
retrieving almost the normal histological architecture of corpus callosum nerve fibers and 
oligodendrocytes population, which were pronounced in subgroup II-B more than subgroup III-B 
demonstrating a duration dependency. This was in line with Stanislaus et al. (2005) [53] who 
reported that NAC treatment decreased inflammatory monocyte/macrophage cells in the CNS of 
rats with acute encephalomyelitis. Similarly, Saraswathy et al. (2014) [54] revealed that NAC at 
doses of 100 and 200 mg/kg could protect the brain tissue against phenytoin-induced brain damage. 
In vitro studies have indicated that NAC can promote the survival of neurons and oligodendrocytes 
by preventing a decrease in the expression of their myelin-related genes, potentially facilitating 
remyelination. NAC can also attenuate oligodendrocyte degeneration caused by lipopolysaccharide 
in the developing rat brain [55]. In addition to Mohammed et al. (2019) [56] who demonstrated that 
supplementation with NAC reduced both histopathological abnormalities and biochemical findings 
induced by doxorubicin in cerebral cortex of albino rats and Fan et al. (2020) [57] who suggested 
that NAC therapy reduced neuronal damage caused by neuroinflammation and apoptosis, which 
was linked to decreased dendritic spine atrophy and synapse deficits in animal model of depression. 
With regard to group IV, in the current thesis, consecutive administration of CPZ and NAC 
showed partial improvement in demyelination events less than that observed in group-III with co-
administration of both drugs. This was supported by Cilio and Ferriero (2010)'s [58] previous work 
in neonates suffering from hypoxic injury after intrauterine infection. Monti et al. (2020) [49] used 
NAC for 2 months in MS patients.  However, those patients have neurological symptoms for years 
and it might be necessary to expand the duration of administration of NAC for several months or 
even years in order to observe its maximum effectiveness in symptom control.  
CPZ recovery group in the present work showed incomplete spontaneous remyelination of 
corpus callosum nerve fibers being more evident in subgroup IV-A than in subgroup IV-B. In a 
previous work of Manrique-Hoyos et al. (2012) [59] they demonstrated that following cessation of 
CPZ supplementation for 5 weeks, animals showed an initial recovery of locomotor performance 
with partial remyelination, a finding which was in line with the current study. Similarly, Zhen et al. 
(2017) [60] demonstrated that removal of CPZ from the diet of animals enhances remyelination of 
CC. Poor remyelination was evident in subgroup IV-B following withdrawal of CPZ. Vana et al. 
(2007) [61] and Zendedel et al. (2013) [14] reported that when CPZ administration is prolonged, 
remyelination is delayed, a process called (chronic demyelination) where the number of damaged 
axons is high. Goldschmidt et al. (2009) [62] and Vega-Riquer et al. (2019) [33] suggested that 
remyelination is a transient phenomenon and remyelinated shadow plaques may be affected by new 
bouts of demyelination, which ultimately lead to incomplete myelin  sheath repair. 
The current immuno-histochemical study showed a decreased myelin basic protein reaction 
(MBP) in CC nerve fibers and oligodendrocytes nuclei over time. The myelin basic protein reaction 
was improved in subgroups II-B and II-C more than subgroups III-B and III-C. In addition, there 
was minimal improvement in subgroup IV-A with no notable improvement in subgroup IV-B. 
Similar findings were recorded by Pohl et al. (2011) [63] who documented progressive reduction of 
immune-labeling for MBP over time in the cerebellar white matter, brainstem, midbrain and spinal 
cord white and grey matter. In addition to widespread progressive vacuolation (status spongiosus) 
in white matter that was present at the onset of clinical signs and increased in size and number over 
time. 
CONCLUSIONS 
In conclusion, administration of CPZ induced demyelination of CC nerve fibers with 
evidence of direct proportion between the duration of CPZ administration and the severity of 
demyelination. The co-administration of CPZ and NAC had a fair protective impact that was 
stronger than the sequential administration of the two drugs. On the basis of these observations, 
NAC has neuroprotective effects and has the potential to be a novel therapeutic approach for the 
treatment of demyelinating disease such as multiple sclerosis; however, treatment should begin as 
soon as the disease manifests. 
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Figure 1. Myelinated nerve fibers of CC. Light microscopic examination of myelination in control 
groups. a. & b. Showing densely packed, myelinated and parallel arranged fibers (▲). The 
oligodendrocytes nuclei (arrows) appear well defined, rounded, darkly stained and arranged in 
longitudinal rows parallel (bracketed by lines) to the nerve fibers that they myelinate. c. Showing 
strong positive myelin basic protein reaction of myelin fibers (▲) and oligodendrocytes nuclei 
(arrows). Electron microscopic examination. d. Showing variable sized densely packed axons (#), 
surrounded by thick dense myelin sheath (arrows) with electron lucent intact cytoplasm. e. Showing 
normal oligodendrocyte with oval dark nucleus (★), regular nuclear envelope, clumped chromatin 
and surrounded by electron lucent cytoplasm (arrows). a. LFB, X400; b. H&E, X400; c. MBP, 




Figure 2. Concomitant administration of NAC protects from CPZ-induced demyelination more 
efficiently than the consecutive treatment by the two drugs. Light microscopic examination of 
demyelination in CPZ-treated group for 4Ws. a. & b. Showing multiple areas of unpacked partially 
demyelinated nerve fibers (▲) with axonal disruption and splitting (X), partial loss of 
oligodendrocytes nuclei, most of them appear dispersed and showing faint staining and karyorrhexis 
(thin arrows), others are circumscribed and darkly stained (thick arrows), Few nuclei are seen oriented 
parallel to the nerve fibers (bracketed by lines). c. Showing moderate positive myelin basic protein 
reaction of myelin fibers (▲) and oligodendrocytes nuclei (arrows).CPZ and NAC treated group. d. 
Showing well-arranged, packed demyelinated nerve fibers (▲) with focal axonal disruption and 
fragmentation (X). e. Preserved disorganized oligodendrocytes nuclei with some of them arranged in 
linear rows (bracketed by lines). Most of them appear rounded and darkly stained with few flattened 
small sized nuclei showing faint staining and karyorrhexis (arrows). f. Showing strong myelin basic 
protein positive reaction of myelin fibers (▲) and positive oligodendrocytes nuclei (arrows) reaction. 
CPZ followed by NAC-treated group g. & h. Showing demyelinated unpacked nerve fibers (▲) with 
focal axonal splitting (X) and dispersed faintly stained oligodendrocyte nuclei (arrows). 
Oligodendrocyte nuclei are seen parallel to the nerve fibers (bracketed by lines). Most of them appear 
round and circumscribed with faint staining (thick arrows) and few appear flattened (thin arrows). i. 
Showing strong positive myelin basic protein reaction of myelin fibers (▲) and oligodendrocytes 
nuclei (arrows). Weak spontaneous remyelination is detected in the short duration (CPZ4Ws) recovery 
group after 4Ws of CPZ cessation. j. & k. Showing disorganized, fragmented, demyelinated nerve 
fibers (▲) with wide areas of vacuolation ( ).Notable loss of oligodendrocytes nuclei with the 
remaining ones appear dispersed, flattened and of small size with faint staining (arrows). l. Showing 
weak myelin basic protein positive reaction of myelin fibers (▲) and moderate oligodendrocytes 
nuclei (arrows). a. LFB, X400; b. H&E, X400; c. MBP, X400. 
 
 
Figure 3. Electron microscopic examination of short duration CPZ-treated group (4Ws). a. Showing 
narrow gapping between unpacked thin myelinated (o) and thick myelinated (▪) axons exhibiting 
redundant sheath (arrows) with some of them showing partial axonal degeneration (*) and inclusion 
bodies ( ). b. Showing oligodendrocyte (★) containing dark nucleus  surrounded by few thick 
myelinated axons (▪) with redundant myelin sheath and focal areas of splitting 
(arrows),unmyelinated (^) and multiple irregular thin myelinated (o) axons. CPZ and NAC-treated 
group c. Showing multiple thick myelinated (▪) and thin myelinated (o) axons with some of them 
exhibiting split, redundant sheath (arrows) as well as degenerated axonal cytoplasm (*) and 
inclusion bodies ( ). d. Showing ovoid, dark nucleus (★) surrounded by rarified cytoplasm (*) and 
is adherent to the nearby axons (#). CPZ followed by the NAC-treated group. e. Showing unpacked 
axons with narrow gapping in between (◄◄). Multiple thin myelinated (o) and few unmyelinated 
(^) axons are seen. few axons exhibit redundant split myelin sheath (arrows) and axonal cytoplasmic 
degeneration (*). f. Showing ovoid, dark nucleus (★) with the surrounded cytoplasm displayed 
connection to multiple variable sized thin myelinated axons (#). The short duration CPZ-recovery 
group. g. Showing multiple thin myelinated (o) and few unmyelinated (^) axons with rarified axonal 
cytoplasm (*) and wide gaps in between (◄◄). The myelin sheaths are irregular with notable 
splitting (black arrows), abnormal folded myelin sheaths are seen (white arrows). h. Showing ovoid, 
dark nucleus (★), surrounded by electron lucent cytoplasm showing multiple vacuoles ($) and 
abnormal folded myelin sheaths (white arrows) with no evidence of axonal connection. (TEM X 




Figure 4. CPZ supplementation for long duration produces massive demyelination and lessens the 
protective effects of NAC. Light microscopic examination of demyelination in long duration CPZ-
treated group (8Ws). a. & b. Showing markedly demyelinated, disorganized and fragmented nerve 
fibers (▲). Loss of oligodendrocytes nuclei with the remaining ones appear disorganized, of small 
size with variable degrees of karyorrhexis and karyolysis (arrows). c. Showing negative myelin basic 
protein reaction of myelin fibers (▲) and oligodendrocytes nuclei (arrows). CPZ and NAC treated 
group d. & e. Showing partially demyelinated unpacked nerve fibers (▲) with scanty areas of 
vacuolation ( ). Most oligodendrocyte nuclei appear rounded, darkly stained with few displaying 
faint staining (arrows) and seen parallel to the nerve fibers (bracketed by lines) with few nuclei appear 
flattened (arrows). f. Showing weak positive myelin basic protein reaction of myelin fibers (▲) and 
moderate positive oligodendrocytes nuclei (arrows). CPZ followed by NAC-treated group g. & h. 
Showing unpacked diffusely demyelinated nerve fibers (▲) with axonal splitting and vacuolation (
). Dispersed oligodendrocyte nuclei, which appear rounded, circumscribed with faint staining (thick 
arrows) and few appear of small size and exhibit karyorrhexis and karyolysis (thin arrows). i. Showing 
positive reaction of oligodendrocytes nuclei (arrows) with weak positive myelin fibers (▲). Poor 
spontaneous remyelination  is detected in the long duration (CPZ 8Ws)  recovery group after 8 weeks 
of CPZ cessation. j. & k. Showing markedly disorganized demyelinated nerve fibers (▲) with diffuse 
vacuolation ( ). The oligodendrocyte nuclei appear dark (thick arrows) and parallel aligned to nerve 
fibers (bracketed by lines), while others appear of small size with faint staining (thin arrows). l. 
Showing weak positive myelin basic protein reaction of myelin fibers (▲) and oligodendrocytes 
nuclei (arrows).a. LFB, X400; b. H&E, X400; c. MBP, X400. 
  
 
Figure 5. Electron microscopic examination CPZ-treated group for 8Ws. a. Showing scanty thin 
myelinated (o) axons with split redundant myelin sheath (arrows). Wide gaps of complete axonal loss 
(◄◄) containing extensive remnants of fragmented degenerated axons (*) and folded collapsed 
myelin sheath (white arrows). b. Showing oval heterochromatic oligodendrocyte nucleus (★) with 
focal nuclear envelop indentation (white arrow) and surrounded by completely degenerated rarified 
cytoplasm (*). CPZ and NAC treated group c. Showing irregularly arranged unpacked multiple thin 
myelinated (o), few myelinated (▪) and unmyelinated (^) axons. Most axons showing redundant sheath 
(arrows) inclusion bodies ( ) and compact myelin sheath (white arrows). d. Showing ovoid, dark 
nucleus (★) with large cytoplasmic vacuoles ($) and inclusion bodies ( ) and connection to 
demyelinated axons (#). CPZ followed by the NAC-treated group. e. Showing wide areas of 
irregularly arranged axons with gaps in between (◄◄). Multiple thin myelinated (o), few 
unmyelinated (^) (▪) axons almost all of them have irregular deformed myelin sheaths with diffuse 
axonal cytoplasmic degeneration (*) and scanty inclusion bodies ( ). f. Showing an ovoid nucleus 
(★) with irregular nuclear envelope (white arrows) and electron dense cytoplasm contain multiple 
mitochondria (⮜), secretory granules (black arrows), and is seen connected to multiple thin myelinated 
axons (#). The CPZ-recovery group g. Showing wide gapping (◄◄) between multiple thin 
myelinated (o) axons with irregular-split and tight-deformed myelin sheaths (arrows) and rarefied 
axonal cytoplasm (*). Multiple fragmented unmyelinated axons (^) are seen. h. Showing rounded, 
dark nucleus (★) surrounded by vacuolated cytoplasm ($) with multiple abnormal folded myelin 
sheaths (white arrows) and connected to few axons (#). (TEM X 15000) (TEM X 8000). 
 
